Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies
Fontvieille E, Viallon V, Recalde M, Cordova R, Jansana A, Peruchet-Noray L, Lennon H, Heath A, Aune D, Christakoudi S, Katzke V, Kaaks R, Inan-Eroglu E, Schulze M, Mellemkjær L, Tjønneland A, Overvad K, Farràs M, Petrova D, Amiano P, Chirlaque M, Moreno-Iribas C, Tin Tin S, Masala G, Sieri S, Ricceri F, Panico S, May A, Monninkhof E, Weiderpass E, Gunter M, Ferrari P, Freisling H. Body mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies. BMC Medicine 2023, 21: 418. PMID: 37993940, PMCID: PMC10666332, DOI: 10.1186/s12916-023-03114-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiological Specimen BanksBody Mass IndexCardiovascular DiseasesDiabetes Mellitus, Type 2HumansNeoplasmsObesityProspective StudiesRisk FactorsUnited KingdomConceptsRisk due to interactionObesity-related cancersRisk of obesity-related cancersBody mass indexHigher body mass indexCardiometabolic diseasesJoint associationsHazard ratioCancer riskIncidence of obesity-related cancersJoint association of body mass indexCardiovascular diseaseConfidence intervalsRisk of overall cancerExcess risk due to interactionAssociation of body mass indexSurrogate measure of adiposityUK Biobank prospective cohortCategories of overweight/obesityUK Biobank (UKBAdditive interactionMass indexCardiometabolic disease statusParticipant data meta-analysisCancer risk reduction